Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing
Press Release — New York, NY — June 14, 2017 — Sichenzia Ross Ference Kesner LLP (“SRFK”) announced today the Firm has represented Immuron Limited (NASDAQ: IMRN) (ASX : IMC), a clinical-stage biopharmaceutical company focused on NASH and OTC products, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at a combined offering price of $10.00.
Each ADS represents 40 shares of the company’s ordinary shares. Immuron raised approximately $6,100,000 in gross proceeds, which will be used to advance their products, platform technologies, working capital, and general corporate purposes.
SRFK successfully advised the process by which Immuron listed its ADSs and warrants on NASDAQ under the symbols “NASDAQ:IMRN and IMRNW” respectively, which began trading on June 9, 2017.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Gregory Sichenzia, Darrin M. Ocasio, and David Manno.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Sichenzia Ross Ference Kesner LLP Congratulates AYTU Biosciences, Inc., on NASDAQ Uplisting - October 19, 2017
- Sichenzia Ross Ference Kesner LLP Represents Joseph Gunnar and Fordham Financial Management in $6.75 Million Registered Direct Offering of Common Stock of Ampio Pharmaceuticals, Inc. - October 18, 2017
- Sichenzia Ross Ference Kesner LLP Advises US Gold Corp. on $2.5 Million Public Offering - October 13, 2017